Press coverage about Shire (NASDAQ:SHPG) has trended somewhat positive this week, Accern Sentiment Analysis reports. Accern identifies positive and negative press coverage by analyzing more than 20 million blog and news sources in real time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Shire earned a media sentiment score of 0.18 on Accern’s scale. Accern also assigned news stories about the biopharmaceutical company an impact score of 45.0571047388142 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the next few days.
Here are some of the news stories that may have effected Accern’s analysis:
- Shire and Rani Therapeutics Enter into Collaboration to Evaluate Use of the Rani Pill™ Technology for the Oral Delivery of Factor Therapy (pharmiweb.com)
- Wired News – Shire and Rani Therapeutics Entered into Collaboration to Evaluate Use of the Rani Pill Technology (finance.yahoo.com)
- Critical Survey: Shire (SHPG) versus Warner Chilcott (WCRX) (americanbankingnews.com)
- Shire (SHPG) Given a $222.00 Price Target by Cantor Fitzgerald Analysts (americanbankingnews.com)
- Rani Therapeutics, Shire Partner To Develop Oral FVIII Delivery – Quick Facts (nasdaq.com)
Shares of Shire (NASDAQ SHPG) traded up $0.67 on Thursday, hitting $143.36. The company’s stock had a trading volume of 925,268 shares, compared to its average volume of 1,137,182. The firm has a market capitalization of $43,423.72, a PE ratio of 9.94, a PEG ratio of 0.80 and a beta of 1.59. Shire has a 12 month low of $137.17 and a 12 month high of $192.15. The company has a debt-to-equity ratio of 0.55, a quick ratio of 0.52 and a current ratio of 0.98.
A number of research analysts recently weighed in on the company. Cantor Fitzgerald reiterated a “buy” rating and issued a $222.00 target price on shares of Shire in a report on Thursday, September 14th. Jefferies Group reiterated a “hold” rating and issued a $206.00 target price (down previously from $216.00) on shares of Shire in a report on Wednesday, August 9th. Royal Bank Of Canada reiterated a “buy” rating and issued a $213.00 target price on shares of Shire in a report on Monday, October 2nd. ValuEngine cut Shire from a “buy” rating to a “hold” rating in a report on Friday, September 1st. Finally, Stifel Nicolaus reiterated a “buy” rating and issued a $245.00 target price on shares of Shire in a report on Sunday, October 8th. One analyst has rated the stock with a sell rating, seven have assigned a hold rating and ten have given a buy rating to the company’s stock. Shire has an average rating of “Buy” and an average price target of $212.18.
ILLEGAL ACTIVITY WARNING: This news story was published by Ticker Report and is the sole property of of Ticker Report. If you are accessing this news story on another domain, it was stolen and reposted in violation of United States & international trademark and copyright law. The original version of this news story can be viewed at https://www.tickerreport.com/banking-finance/3080494/shire-shpg-receiving-somewhat-favorable-news-coverage-analysis-shows.html.
Shire plc is a biotech company focused on serving people with rare diseases and other specialized conditions. The Company’s segment is engaged in research, development, licensing, manufacturing, marketing, distribution and sale of specialist medicines. It focuses its development resources on projects in various therapeutic areas (TAs), including Neuroscience, Ophthalmology, Hematology, Oncology, Immunology, Gastrointestinal (GI)/Metabolic/Endocrinology Diseases.
Receive News & Ratings for Shire PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shire PLC and related companies with MarketBeat.com's FREE daily email newsletter.